Jivolar (Metformin Hydrochloride, Sitagliptin)

Jivolar is an oral antidiabetic medication used to improve glycaemic control in type 2 diabetes mellitus.

• Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels.
• Adjunct to diet and exercise: helps patients achieve target HbA1c when lifestyle changes alone are insufficient.
• Combination therapy: used when metformin or sitagliptin monotherapy does not provide adequate control.

• Metformin Hydrochloride decreases hepatic gluconeogenesis and enhances peripheral insulin sensitivity, while Sitagliptin selectively inhibits dipeptidyl peptidase‑4 (DPP‑4), prolonging endogenous incretin activity and promoting glucose‑dependent insulin secretion, together resulting in reduced blood glucose concentrations.

Common Side Effects

• Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea.
• Headache: mild to moderate intensity.
• Mild hypoglycaemia: especially when combined with other glucose‑lowering agents.

Serious or Rare Side Effects

• Lactic acidosis: a rare but potentially fatal metabolic complication.
• Severe hypoglycaemia: can occur with concomitant insulin or sulfonylureas.
• Pancreatitis: acute inflammation of the pancreas.
• Allergic reactions: rash, angioedema, or anaphylaxis.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Jivolar should be used with careful monitoring of renal and hepatic function and awareness of hypoglycaemia risk.

• Renal function monitoring: assess eGFR before initiation and periodically thereafter.
• Hepatic function monitoring: evaluate liver enzymes at baseline and during therapy.
• Risk of lactic acidosis: avoid in patients with severe renal impairment or acute heart failure.
• Use with caution in elderly patients: increased susceptibility to adverse events.
• Contraindicated in severe heart failure: may exacerbate metabolic acidosis.
• Store at room temperature: keep in the original pack, protect from moisture.

Jivolar may interact with several drug classes, requiring dose adjustments or monitoring.

Major Interactions (Avoid)

• Other biguanides (e.g., phenformin): increase risk of lactic acidosis.
• Insulin secretagogues (sulfonylureas, meglitinides): potentiate hypoglycaemia.
• Iodinated contrast agents: may precipitate acute renal failure.
• Alcohol excess: heightens lactic acidosis risk.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): raise sitagliptin levels.

Moderate Interactions (Monitor Closely)

• Diuretics (thiazides, loop diuretics): affect renal clearance of metformin.
• ACE inhibitors/ARBs: combined impact on renal function.
• NSAIDs: may reduce renal perfusion, increasing metformin accumulation.
• Beta‑blockers: can mask hypoglycaemia symptoms.
• Warfarin: monitor INR as sitagliptin may alter anticoagulant effect.